METHODS FOR SENTINEL LYMPH NODE DETECTION IN PATIENTS WITH BREAST CANCER

Objective: to provide various methods for sentinel lymph node detection considering their advantages and disadvantages.

Material and Methods. The search of the relevant articles published in Pubmed, MedLine, RINTs, etc. database was conducted. 49 publications from 1970 to 2018 were analyzed.

Results. Currently, sentinel lymph node biopsy (SLN biopsy) has become a worthy alternative to traditional lymphatic surgery for early breast cancer. SLN biopsy significantly decreases the number of postoperative complications caused by lymphadenectomy and improves the quality of life of cancer patients. So far, a large number of SLN detection techniques have accumulated. Each of these techniques has its own advantages and disadvantages.

Conclusion. Despite a large number of SLN detection methods, the question of the optimal technique is currently debatable. 

1. Kett K., Varga G., Lukács L. Direct lymphography of the breast. Lymphology. 1970; 1: 3–12.

2. Giuliano A.E., Kirgan D.M., Guenther J.M., Morton D.L. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994 Sep; 220(3): 391–8; discussion 398–401. doi: 10.1097/00000658-199409000-00015.

3. Morton D.L., Wen D.R., Wong J.H., Economou J.S., Cagle L.A., Storm F.K., Foshag L.J., Cochran A.J. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992 Apr; 127(4): 392–9. doi: 10.1001/archsurg.1992.01420040034005.

4. Cimmino V.M., Brown A.C., Szocik J.F., Pass H.A., Moline S., De S.K., Domino E.F. Allergic reactions to isosulfan blue during sentinel node biopsy a common event. Surgery. 2001; 130(3): 439–42. doi: 10.1067/msy.2001.116407.

5. Albo D., Wayne J.D., Hunt K.K., Rahlfs T.F., Singletary S.E., Ames F.C., Feig B.W., Ross M.I., Kuerer H.M. Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. Am J Surg. 2001 Oct; 182(4): 393–8. doi: 10.1016/s0002-9610(01)00734-6.

6. Coleman R.L., Whitten C.W., O’Boyle J., Sidhu B. Unexplained decrease in measured oxygen saturation by pulse oximetry following injection of Lymphazurin 1% (isosulfan blue) during a lymphatic mapping procedure. J Surg Oncol. 1999 Feb; 70(2): 126–9. doi: 10.1002/(sici)1096-9098(199902)70:23.0.co;2-p.

7. Momeni R., Ariyan S. Pulse oximetry declines due to intradermal isosulfan blue dye: a controlled prospective study. Ann Surg Oncol. 2004 Apr; 11(4): 434–7. doi: 10.1245/ASO.2004.05.015.

8. Sadiq T.S., Burns W.W., Taber D.J., Damitz L., Ollila D.W. Blue urticaria: a previously unreported adverse event associated with isosulfan blue. Arch Surg. 2001 Dec; 136(12): 1433–5. doi: 10.1001/archsurg.136.12.1433.

9. Sprung J., Tully M.J., Ziser A. Anaphylactic reactions to isosulfan blue dye during sentinel node lymphadenectomy for breast cancer. Anesth Analg. 2003 Apr; 96(4): 1051–3. doi: 10.1213/01.ane.0000048709.61118.52.

10. Wöhrl S., Focke M., Hinterhuber G., Stingl G., Binder M. Near-fatal anaphylaxis to patent blue V. Br J Dermatol. 2004 May; 150(5): 1037–8. doi: 10.1111/j.1365-2133.2004.05931.x.

11. Association of Breast Surgery Guidelines, Association of Breast Surgery; Use of Blue dye for SLNB 2009. 2012; 1–3.

12. Tsopelas C., Sutton R. Why certain dyes are useful for localizing the sentinel lymph node. J Nucl Med. 2002; 10 (43): 1377–1382.

13. Ghiassi S., Sun Y.S., Kim V.B., Scott C.M., Nifong L.W., Rotondo M.F., Chitwood Jr.W.R. Methylene Blue Enhancement of Resuscitation After. J Trauma Acute Care Surg. 2004; 57(3): 515–521.

14. Peek M.C., Charalampoudis P., Anninga B., Baker R., Douek M. Blue dye for identification of sentinel nodes in breast cancer and malignant melanoma: a systematic review and meta-analysis. Future Oncology. 2017; 5(13): 455–467. doi: 10.2217/fon-2016-0255.

15. Cody H.S. Sentinel lymph node mapping in breast cancer. Breast cancer (Tokyo, Japan). 1999; 1 (6): 13–22.

16. Giammarile F., Alazraki N., Aarsvold J.N., Audisio R.A., Glass E., Grant S.F., Oyen W.J. The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. Eur J Nucl Med Mol Imag. 2013; 12 (40): 1932–1947.

17. Kim T., Giuliano A.E., Lyman G.H. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006; 1 (106): 4–16.

18. He P.S., Li F., Li G.H., Guo C., Chen T.J. The combination of blue dye and radioisotope versus radioisotope alone during sentinel lymph node biopsy for breast cancer: A systematic review. BMC Cancer. 2016; 16: 107. doi: 10.1186/s12885-016-2137-0.

19. Dashyan G.A., Krivorotko P.V., Novikov S.N. Biopsy of sentinel lymph nodes in breast cancer. SPb., 2015. 44 p. (in Russian).

20. Doroshenko A., Chernov V., Medvedeva A., Zeltchan R., Slonimskaya E., Varlamova N., Sinilkin I., Skuridin V., Dergilev A. The first experience of using of 99mTc-Al2O3 for detection of sentinel lymph nodes in breast cancer. IOP Conference Series: Materials Science and Engineering 2016. 135(1): 012011.

21. Goyal A. New Technologies for Sentinel Lymph Node Detection. Breast Care. 2018; 5 (13): 349–353. doi: 10.1159/000492436.

22. DSouza A.V., Lin H., Henderson E.R., Samkoe K.S., Pogue B.W. Review of fluorescence guided surgery systems: identification of key performance capabilities beyond indocyanine green imaging. J Biomed Optics. 2016; 8 (21): 080901. doi: 10.1117/1.JBO.21.8.080901.

23. Papathemelis T., Jablonski E., Scharl A., Hauzenberger T., Gerken M., Klinkhammer-Schalke M., Scharl S. Sentinel lymph node biopsy in breast cancer patients by means of indocyanine green using the Karl Storz VITOM® fluorescence camera. J BioMed Res Intern. 2018; 10(6251468): 1–8. doi: 10.1155/2018/6251468.

24. Grischke E.M., Röhm C., Hahn M., Helms G., Brucker S., Wallwiener D. ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes in Breast Cancer: Results of a Prospective Open-label Clinical Trial. Geburtshilfe und Frauenheilkunde. 2015; 9(75): 935–940. doi: 10.1055/s-0035-1557905.

25. Ballardini B., Lissidini G., Veronesi P. The indocyanine green method is equivalent to the (99m) Tc-labeled radiotracer method for identifying the sentinel node in breast cancer: A concordance and validation study. Fluorescence Imaging for Surgeons: Concepts and Applications. 2015; 12(39): 255–266.

26. Samorani D., Fogacci T., Panzini I., Frisoni G., Accardi F.G., Ricci M., Tassinari D. The use of indocyanine green to detect sentinel nodes in breast cancer: a prospective study. Eur J Surg Oncol. 2015; 1 (41): 64–70. doi: 10.1016/j.ejso.2014.10.047.

27. Schaafsma B.E., Verbeek F.P., Rietbergen D.D., van der Hiel B., van der Vorst J.R., Liefers G.J., Vahrmeijer A.L. Clinical trial of combined radio- and fluorescence-guided sentinel lymph node biopsy in breast cancer. Br J Surg. 2013; 8(100): 1037–1044.

28. Sugie T., Sawada T., Tagaya N., Kinoshita T., Yamagami K., Suwa H., Toi, M. Comparison of the indocyanine green fluorescence and blue dye methods in detection of sentinel lymph nodes in early-stage breast cancer. Ann Surg Oncol. 2013; 7(20): 2213–2218.

29. Xiong L., Gazyakan E., Yang W., Engel H., Hünerbein M., Kneser U., Hirche C. Indocyanine green fluorescence-guided sentinel node biopsy: A meta-analysis on detection rate and diagnostic performance. Eur J Surg Oncol. 2014; 7 (40): 843–849. doi: 10.1016/j.ejso.2014.02.228.

30. Zhang X., Li Y., Zhou Y., Mao F., Lin Y., Guan J., Sun Q. Diagnostic Performance of Indocyanine Green-Guided Sentinel Lymph Node Biopsy in Breast Cancer : A Meta-Analysis. PLoS ONE. 2016; 6(11): 1–12. doi: 10.1371/journal.pone.0155597.

31. Ahmed M., Purushotham A.D., Douek M. Novel techniques for sentinel lymph node biopsy in breast cancer : a systematic review. Lancet Oncol. 2014; 8(15): e351–e362. doi: 10.1016/S1470-2045(13)70590-4.

32. Sugie T., Ikeda T., Kawaguchi A., Shimizu A., Toi M. Sentinel lymph node biopsy using indocyanine green fluorescence in early stage breast cancer : a metaanalysis. Int J Clin Oncol. 2016; 22(1): 11–17. doi: 10.1007/s10147-016-1064-z.

33. Marmor M.F., Ravin J.G. Fluorescein Angiography. Arch Ophthalmol. 2011; 7(129): 943.

34. Okuda T., Kataoka K., Yabuuchi T., Yugami H., Kato A. Fluorescence-guided surgery of metastatic brain tumors using fluorescein sodium. J Clin Neurosci. 2010; 1(17): 118–121.

35. Okuda T., Yoshioka H., Kato A. Fluorescence-guided surgery for glioblastoma multiforme using high-dose fluorescein sodium with excitation and barrier filters. J Clin Neurosci. 2012; 12(19): 1719–1722.

36. Haven N. 1% Lymphazurin vs 10% Fluorescein for Sentinel Node Mapping in Colorectal Tumors. Arch Surg. 2004; 139: 1180–1184.

37. Srivasatava A., Suresh J., Ranjan P., Kumar A., Kataria K., Dhar A., Vathulru S. Fluorescent fluorescein with methylene blue compared to radioactive sulphur colloid with methylene blue: a randomised comparison. Proc SABCS. 2017; abstr.: PD2-03.

38. Harisinghani M.G., Weissleder R. Sensitive, noninvasive detection of lymph node metastases. PLoS Med. 2004; 1: 66. doi: 10.1371/journal.pmed.0010066.

39. Harisinghani M.G., Barentsz J., Hahn P.F., Deserno W.M., Tabatabaei S., van de Kaa C.H., Weissleder R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003; 348: 2491–2499. doi: 10.1056/NEJMoa022749.

40. Belyanina I.V., Zamay S.S., Colovskaya O.S., Zamay G.S., Garanzha I.V., Grigoryeva V.V., Glazyrin Yu. E., Zamay T.N., Kichkaylo A.S. Address antitumor therapy using bioconjugates of magnetic nanoparticles with DNA-aptamers. Siberian Medical Review. 2016; 101(5): 77–78. (in Russian).

41. Yu M.K., Park J., Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics. 2012; 1(2): 3–44.

42. Zada A., Peek M.C.L., Ahmed M., Anninga B., Baker R., Kusakabe M., Douek M. Meta-analysis of sentinel lymph node biopsy in breast cancer using the magnetic technique. Br J Surg. 2016; 11(103): 1409–19. doi: 10.1002/bjs.10283.

43. Abe H., Teramoto A., Yamasaki K., Yoneda, K., Ogawa M., Kawasaki M., Kameyama M. The combination of preoperative computed tomography lymphography and intraoperative fluorescence imaging navigation for sentinel lymph node biopsy of early breast cancer patients. J Clin Oncol. 2017; 35 (suppl): 567.

44. Nakagawa M., Morimoto M., Takechi H., Tadokoro Y., Tangoku A. Preoperative diagnosis of sentinel lymph node (SLN) metastasis using 3D CT lymphography (CTLG). Breast Cancer. 2016; 3 (23): 519–524. doi: 10.1007/s12282-015-0597-8.

45. Yamamoto S., Suga K. Breast sentinel lymph node navigation with three-dimensional computed tomography – lymphography : a 12-year study. Breast Cancer. 2016; 3 (23): 456–462. doi: 10.1007/s12282-015-0584-0.

46. Greis C. Technology overview: SonoVue (Bracco, Milan). Eur Radiol. 2004; 14 (suppl 8): 11–15.

47. Sidhu P.S., Choi B.I., Nielsen M.B. The EFSUMB Guidelines on the non-hepatic clinical applications of contrast enhanced ultrasound (CEUS): a new dawn for the escalating use of this ubiquitous technique. Ultraschall in Med. 2012; 33: 5–7.

48. Sever A.R., Mills P., Jones S.E., Cox K., Weeks J., Fish D., Jones P.A. Preoperative sentinel node identification with ultrasound using microbubbles in patients with breast cancer. Am J Rentgenol. 2011; 2(196): 251–256. doi: 10.2214/AJR.10.4865.

49. Omoto K., Matsunaga H., Take N., Hozumi Y., Takehara M., Omoto Y., Kawano M. Sentinel node detection method using contrastenhanced ultrasonography with sonazoid in breast cancer: preliminary clinical study. Ultrasound Med Biol. 2009; 8(35): 1249–1256.

50. Moody A.N., Bull J., Culpan A.M., Munyombwe T., Sharma N., Whitaker M., Wolstenhulme S. Preoperative sentinel lymph node identification, biopsy and localisation using contrast enhanced ultrasound (CEUS) in patients with breast cancer: a systematic review and meta-analysis. Clin Radiol. 2017; 11 (72): 959–971. doi: 10.1016/j.crad.2017.06.121.